Polyzene-F Makes the Difference

Fast, Quality Healing*

COBRA PzF NCS is nanocoated with a revolutionary drug-free polymer called Polyzene-F (PzF). PzF is distinctly superior from other polymers due to its high biocompatibility, ultra-purity, elasticity and ultra-high molecular weight.

The proprietary PzF polymer is imparted with the following unique properties:

  • Anti-thrombogenic
  • Anti-inflammatory
  • Rapid & complete healing*1-5

Preclinical and Clinical Evaluation of COBRA PzF NCS

Passivation & Pro-Healing Properties

Passivation & Pro-Healing Properties

Through a process called passivation, albumin preferentially binds to the PzF coating, preventing fibrinogen deposition and subsequent platelet adhesion and activation, resulting in clotting resistance and accelerated healing.*1-5

View PzF Publications

Significant Thromboresistance

COBRA PzF NCS exhibited 3x greater thromboresistance than SYNERGY™ and showed no significant difference to XIENCE™.*5

Clot Formation at 1 Hour
COBRA PzF NCS 1.7
COBRA PzF NCS 1.7
SYNERGY 5.2
SYNERGY 5.2
XIENCE 0.88
XIENCE 0.88
Method: Porcine shunt model, Immunofluorescent Staining (IS) / 1 hour / N=8 / COBRA PzF vs SYNERGY, p=0.153; COBRA PzF vs XIENCE, p=0.017

Rapid & Complete Strut Coverage

COBRA PzF NCS demonstrated significantly greater strut coverage than SYNERGY and XIENCE.*5

Strut Coverage at 14 Days
COBRA PzF NCS 99%
COBRA PzF NCS 99%
SYNERGY 18%
SYNERGY 18%
XIENCE 30%
XIENCE 30%
Method: In-Vivo rabbit Iliofemoral artery, scanning electron microscope (SEM) images / 14 days / N=6 / COBRA PzF vs SYNERGY, p<0.001; COBRA PzF vs XIENCE, p<0.001

Higher Functioning Endothelium

COBRA PzF NCS exhibited 2.5-3x higher functioning endothelium, compared to SYNERGY, XIENCE, and BioFreedom™.*5

Blue coloration indicates areas of incomplete endothelialization.
Endothelial Function at 28 Days
COBRA PzF NCS 22%
COBRA PzF NCS 22%
XIENCE 71%
XIENCE 71%
SYNERGY 66%
SYNERGY 66%
BIOFREEDOM 55%
BIOFREEDOM 55%
Rabbit model / 28 days / N=4 / COBRA PzF vs SYNERGY, p=0.033; COBRA PzF vs XIENCE, p=0.030

On-Demand Webinar

Understanding the Science Behind COBRA PzF NCS: A New Category of Stent

View Webinar
* AS DEMONSTRATED IN HUMAN AND PRECLINICAL STUDIES.
Correlation between bench testing, animal studies and humans have not been determined.
  1. Koppara T, Sakakura K, Pacheco E, et al. Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology. 2016; 222:217-225.
  2. Mrowietz C, Franke R, Seyfert U, et al. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clinical Hemorheology and Microcirculation. 2005; 32:89–103.
  3. Richter G, Stampfl U, Stampfl S, et al. A New Polymer Concept for Coating of Vascular Stents Using PTFEP (poly(bis(trifluoroethoxy)phosphazene) to Reduce Thrombogenicity and Late In-Stent Stenosis. Investigative Radiology. 2005; 40(4):210-218.
  4. Radeleff B, Thierjung H, Stampfl U, et al. Restenosis of the CYPER-Select, TAXUS-Express, and Polyzene-F NanoCoated Cobalt-Chromium Stents in the Minipig Coronary Artery Model. Cardiovasc Intervent Radiol. 2007
  5. Jinnouchi, H, Mori H, et al. Thromboresistance and Functional Healing in the COBRA PzF Stent versus Competitor DES: Implications for Dual Anti-Platelet Therapy. EuroIntervention. 2018 Oct. Online ahead of print.